MINNEAPOLIS, Feb. 27, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences:
TD Cowen 45th Annual Health Care Conference
March 4, 2025
2:30 PM EST
Leerink Partners Global Healthcare Conference
March 11, 2025
11:20 AM EDT
Barclays 27th Annual Global Healthcare Conference
March 12, 2025
10:00 AM EDT
A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.
Contact: David Clair, Vice President, Investor Relations & Corporate Development
This email address is being protected from spambots. You need JavaScript enabled to view it.
612-656-4416
| Last Trade: | US$49.63 |
| Daily Change: | -0.72 -1.43 |
| Daily Volume: | 1,569,743 |
| Market Cap: | US$7.890B |
April 24, 2025 April 23, 2025 February 20, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
